ClinicalTrials.gg
CompletedNCT02455856Updated Jul 11, 2017

Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants

A Phase 1 interventional study of JNJ-42847922 and Itraconazole in Healthy, sponsored by Janssen Cilag N.V./S.A.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Janssen Cilag N.V./S.A. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the effects of repeated once daily administration of 200 milligram (mg) of itraconazole (steady state) on the single-dose pharmacokinetics of JNJ 42847922 in healthy, male participants.

Read the detailed description

This is an open-label (all people know the identity of the intervention), fixed-sequence, single-center, single-dose study designed to assess the effects of steady-state itraconazole exposure on the pharmacokinetics of a single oral dose of JNJ 42847922 in healthy male participants. The duration of study will be approximately of 6 weeks per participant. The study consists of 3 parts: Screening (that is, 21 days before study commences on Day 1); Open-label Treatment (6 days); and Follow-up (7 to 14 days after last dose of study drug or early withdrawal).

All eligible participants will receive single oral doses of 5 milligram (mg) JNJ-42847922 on Day 1 and Day 6. A daily dose of 200 mg itraconazole will be administered from Day 2 to Day 6. Followed by an overnight fast of at least 8 hours participants will be administered with study treatment 30 minutes after light breakfast. Participants will not be allowed to have food until 4 hours of drug administration. Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Itraconazole
  • JNJ-42847922
03

In context

Lead sponsor

Janssen Cilag N.V./S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants aged between 18 and 55 years, inclusive
  • (BMI) between 18 and 30 kilogram/meter\^2 inclusive (BMI = weight/height\^2)
  • Nonsmoker (not smoked for at least 3 months prior to screening)
  • Men who are sexually active with a woman of and have not had a vasectomy must agree to use a barrier method of e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partners should also use an appropriate method of birth control for at least the same duration
  • Participants must have signed an document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions

Exclusion criteria

Exclusion Criteria:

  • abnormal values for hematology, clinical chemistry or urinalysis at screening or admission
  • Clinically significant abnormal physical examination, vital signs or 12-lead at screening, on Day -1 or on Day 1, predose
  • History of or current significant psychiatric and other illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the subject. History of epilepsy or fits or unexplained black-outs
  • Serology positive for surface antigen (HBsAg), antibodies (HCV) or (HIV) antibodies
  • History of clinically significant drug and/or food allergies
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    JNJ-42847922 plus Itraconazole

    Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.

    Drug: JNJ-42847922 · Drug: Itraconazole

Interventions

  • Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.

  • Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of JNJ-42847922

    The Cmax is the maximum plasma concentration.

    Time frame: up to Day 6

  2. Time to Reach Maximum Concentration (tmax) of JNJ-42847922

    The tmax is time to reach the maximum observed plasma concentration.

    Time frame: up to Day 6

  3. Time to Reach Last Quantifiable Plasma Concentration (tlast) of JNJ-42847922

    The tmax is time to last observed quantifiable plasma concentration.

    Time frame: up to Day 6

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-42847922

    The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

    Time frame: up to Day 6

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-42847922

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: up to Day 6

  6. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of JNJ-42847922

    The AUC (0-24) is the area under the plasma concentration-time curve from time 0 to time 24 hours

    Time frame: up to Day 6

  7. Elimination Half-Life (t [1/2] Lambda) of JNJ-42847922

    Elimination half-life (t \[1/2\] Lambda) is associated with the terminal slope (lambda \[z\]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/lambda(z).

    Time frame: up to Day 6

  8. Rate Constant (Lambda[z])

    Lambda(z) is first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

    Time frame: up to Day 6

  9. Apparent total body clearance (CL/F) of JNJ-42847922

    Clearance is a quantitative measure of the rate at which a drug substance is removed from the body. The CL/F will be calculated by dividing the dose by AUC (0-infinity)

    Time frame: up to Day 6

  10. Apparent volume of distribution at the terminal Phase (Vd[z] /F) of JNJ-42847922

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.The Vd(z)/F will be calculated by dividing CL/F by lambda(z).

    Time frame: up to Day 6

  11. Mean Residence Time of JNJ-42847922

    Mean residence time, calculated as area under the first moment curve (AUMC\[0-infinity\]/AUC(0-infinity).

    Time frame: up to Day 6

  12. Amount of JNJ-42847922 Excreted in Urine (Ae)

    amount excreted into the urine, calculated by multiplying the urinary volume with the urinary concentration.

    Time frame: up to Day 6

  13. Percentage of JNJ-42847922 Dose Excreted in Urine

    Amount excreted into the urine, expressed as a percentage of the administered dose, calculated as \[Ae/dose\]\*100, and corrected for molecular weight when necessary.

    Time frame: up to Day 6

  14. Renal Clearance

    Renal clearance calculated as Ae (total)/AUC (infinity).

    Time frame: up to Day 6

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: up to End of study (7 to 14 days after lasr dose of study drug or early withdrawal)

07

Study locations

1 site
  • Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in Jun 2015, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2015
First posted
May 28, 2015
StartActual
May 18, 2015
Primary completionActual
Jun 19, 2015
CompletionActual
Jun 19, 2015
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02455856
Responsible party
Sponsor
First posted
May 28, 2015
Start date
May 18, 2015
Primary completion
Jun 19, 2015
Completion
Jun 19, 2015
Last update
Jul 11, 2017

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion